Jun 5, 2023 07:01AM
Jun 5, 2023 07:00AM
May 15, 2023 04:51PM
May 15, 2023 04:50PM
May 11, 2023 08:30AM
Mar 31, 2023 08:30AM
Mar 6, 2023 08:31AM Bellerophon Therapeutics (BLPH) Announces $5 Million Registered Direct Offering of Common Stock, Warrants
Mar 6, 2023 08:30AM
Feb 9, 2023 08:32AM
Feb 9, 2023 08:30AM
Jan 18, 2023 04:12PM
Jan 18, 2023 04:05PM
Jan 5, 2023 08:34AM
Jan 5, 2023 08:30AM Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Nov 14, 2022 08:30AM
Sep 27, 2022 08:30AM
Sep 27, 2022 08:30AM
Aug 15, 2022 08:30AM
May 11, 2022 08:30AM
Mar 31, 2022 04:01PM
Dec 17, 2021 08:30AM Bellerophon Therapeutics (BLPH) Reports ositive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse for Treatment of Pulmonary Hypertension Associated with Sarcoidosis
Dec 17, 2021 08:30AM
Nov 15, 2021 08:30AM
Aug 5, 2021 08:30AM
May 26, 2021 08:31AM
May 26, 2021 08:30AM
May 11, 2021 08:30AM
Mar 11, 2021 08:30AM Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Dec 1, 2020 08:33AM
Dec 1, 2020 08:30AM
Nov 23, 2020 08:32AM
Nov 23, 2020 08:30AM
Nov 5, 2020 08:30AM
Oct 29, 2020 08:30AM
Aug 11, 2020 08:37AM Bellerophon Therapeutics (BLPH) Appoints Wassim Fares, M.D., MSCR, as Chief Medical Officer
Aug 11, 2020 08:30AM
Aug 5, 2020 08:30AM
Jul 15, 2020 08:32AM
Jul 15, 2020 08:30AM
Jul 13, 2020 08:30AM
Jun 29, 2020 08:00AM
May 22, 2020 09:47AM Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares
May 19, 2020 07:04AM
May 19, 2020 07:00AM
May 18, 2020 04:03PM
May 18, 2020 04:03PM
May 11, 2020 04:01PM
May 11, 2020 08:34AM
May 11, 2020 08:30AM Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19
May 4, 2020 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All